Figure 1
The potential utility for miR-predictive signatures in personalising the management of cancer and radiotherapy treatment. Using prostate cancer as an example, validated miR signatures could assist in determining which patients undergoing active surveillance should proceed to definitive treatment. In addition, they could aid in identifying those patients who potentially require additional radiotherapy dose escalation due to a cancer radioresistant signature, or are at increased risk of developing significant normal tissue radiotoxicity.
